Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preventing dangerous drug interactions.

S Piscitelli1

  • 1Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Md., USA.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)
|October 13, 2000
PubMed
Summary

Understanding drug interaction mechanisms is crucial for pharmacists to prevent dangerous medication combinations. Always review all drugs, including supplements, to identify potential risks, especially in patients with multiple prescriptions or herbal product use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure.

European heart journal. Cardiovascular Imaging·2015
Same author

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.

HIV clinical trials·2013
Same author

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Antimicrobial agents and chemotherapy·2001
Same author

Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Journal of clinical microbiology·2000
Same author

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
Same author

A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.

Clinical nephrology·1999

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Drug Safety

Background:

  • Most drug interactions are clinically minor, but some present significant health risks.
  • Identifying and managing drug interactions is a key responsibility for healthcare professionals.
  • A foundational understanding of drug interaction mechanisms aids in risk assessment.

Purpose of the Study:

  • To emphasize the importance of understanding drug interaction mechanisms for pharmacists.
  • To guide pharmacists in identifying and preventing potentially harmful drug combinations.
  • To highlight the necessity of comprehensive medication history review.

Main Methods:

  • Review of clinical significance of drug interactions.
  • Emphasis on the role of mechanistic knowledge in risk assessment.
  • Guidance on comprehensive medication history taking.

Main Results:

  • Knowledge of drug interaction mechanisms empowers pharmacists to identify risks.
  • Thorough medication reviews are essential for uncovering potential interactions.
  • Certain patient populations (polypharmacy, herbal product users) require heightened vigilance.

Conclusions:

  • Pharmacists play a vital role in mitigating risks associated with drug interactions.
  • A proactive approach, including detailed medication history, is key to patient safety.
  • Understanding the 'why' behind interactions improves the ability to prevent adverse events.

Related Experiment Videos